AC
CCCC icon

AXQ Capital’s C4 Therapeutics CCCC Stock Holding History

AXQ Capital’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.2K Sell
10,745
-75,533
-88% -$258K 0.01% 911
2026
Q1 		$227K Buy
+86,278
New +$203K 0.03% 695

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AXQ Capital's CCCC Position: Q2 2026 in Review

AXQ Capital reduced its C4 Therapeutics (CCCC) stake by 88% in Q2 2026, selling an estimated $258K and leaving 10,745 shares worth $50.2K. The position accounts for 0.01% of the portfolio, ranked #911.

AXQ Capital first reported a position in CCCC in Q1 2026 and has held it in 2 quarters since. The position peaked at $227K in Q1 2026. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • AXQ Capital held 10,745 shares of C4 Therapeutics worth $50.2K as of Q2 2026.
  • AXQ Capital sold 75,533 C4 Therapeutics shares in Q2 2026, an estimated $258K.
  • C4 Therapeutics made up 0.01% of AXQ Capital's portfolio in Q2 2026, its #911 holding.
  • AXQ Capital first reported a position in C4 Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • AXQ Capital's C4 Therapeutics position peaked at $227K in Q1 2026.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.